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Health-related quality of life in Italian patients
with systemic lupus erythematosus. I. Relationship
between physical and mental dimension and
impact of age
S. Rinaldi, A. Doria, F. Salafﬁ2, M. Ermani1, L. Iaccarino, A. Ghirardello,
S. Zampieri, P. Sarzi-Puttini3, P. F. Gambari and G. Perini1
Objective. To examine health-related quality of life (HRQOL) in Italian patients with systemic lupus erythematosus (SLE) and
compare it with that of healthy people, and to investigate relationships among different dimensions and subscales of a generic
health status measure.
Methods. The Medical Outcomes Study Short Form-36 (SF-36) was applied in a cohort of 126 consecutive SLE patients and
96 healthy controls. At the time of HRQOL testing, all patients underwent clinical and laboratory evaluation.
Results. Both physical (PCS) and mental (MCS) component summary scores of the SF-36 were reduced in patients compared
with controls. In SLE great variability in all the subscales was observed. Signiﬁcant correlations between PCS and MCS and
between many different subscales were observed in patients but not in controls. The PCS was higher than MCS more frequently
in controls than in SLE patients (81 vs 48.4%, P<0.00001). In SLE, HRQOL tended to worsen with age.
Conclusion. Both PCS and MCS contribute to the decrease in HRQOL in SLE patients. In SLE the mutual interaction
between these two dimensions seems to be more relevant than in healthy people.
KEY WORDS: SF-36, Health-related quality of life, Mental health, Physical health, Systemic lupus erythematosus.
Over the past few years, the assessment of health-related quality of
life (HRQOL) in systemic lupus erythematosus (SLE) has become
a relevant tool in deﬁning disease prognosis and the effectiveness of
therapeutic intervention [1, 2].
During the last decade, several studies on the HRQOL of SLE
patients have been carried out which have recognized the impor-
tance of the disease assessment not only from a biological but also
from a psychosocial point of view [3, 4]. In order to select the most
suitable tools for deﬁning health status in SLE patients, some
authors have analysed different generic health status instruments
designed to summarize a spectrum of HRQOL that applies to
many different impairments, patients and populations [5]. Apart
from their broad applicability, they may be able to detect unex-
pected beneﬁcial and adverse effects on disease remission and
progression that can easily be missed by speciﬁc measures. The
Medical Outcomes Study Short Form-20 (SF-20) and the Short
Form-36 (SF-36) were the generic health status instruments which
performed better in SLE [6]. In view of the comprehensiveness of
the SF-36, its widespread use and international validation for a
wide range of medical conditions, we choose it as a patient life-
impact assessment, although it is not yet known what degree of
change in SF-36 score is clinically important.
Our objectives were to examine health status in Italian SLE
patients using SF-36, compared with that of healthy controls, and
to study the relationships among its different health dimensions
and the impact of age class. Our ﬁndings may help patient
management in clinical practice.
Patients and methods
Patients with SLE
We considered 126 consecutive out-patients affected with SLE seen
in the rheumatology unit at the Division of Rheumatology, Padua
University. They were all Caucasians. There were 110 females and
16 males, mean age was 38.9 11.9 yr (range 18–65) and mean
disease duration 9.9 6.3 yr (range 1–32).
All patients satisﬁed at least four of the American College of
Rheumatology (ACR) criteria for the classiﬁcation of SLE [7] and
had always been followed up according to the diagnostic and
therapeutic guidelines reported by ACR [8].
SLE clinical and laboratory parameters, disease activity and
cumulative damage, and treatment were evaluated.
For deﬁnitions of SLE-speciﬁc features, we used those included
in the ACR criteria [7].
Antinuclear antibodies (ANA) and anti-double-stranded DNA
(dsDNA) were detected with the indirect immunoﬂuorescence
technique, using as a substrate HEp-2 cells and Crithidia luciliae
respectively. Antibodies against extractable nuclear antigens (anti-
Sm, anti-nRNP, anti-Ro/SSA, anti-La/SSB) were tested with the
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counterimmunoelectrophoresis technique, using as control sera
those provided by the Center for Disease Control (Atlanta, GA,
USA). Lupus anticoagulant was detected by means of the Russell
viper venum time method, and anticardiolipin antibodies by an
enzyme-linked immunosorbent assay.
SLE disease activity was measured with the European
Consensus Lupus Activity Measure (ECLAM) score [9] and
cumulative damage with the Systemic Lupus International
Collaborating Clinic/American College of Rheumatology
(SLICC/ACR) damage index [10]. An ECLAM score greater
than 2 was considered indicative of active disease.
Ninety-six subjects, selected by the Department of
Rheumatology, University of Ancona, were considered as con-
trols. The control group was chosen randomly from a list of 430
hospital personnel, and included 80 females and 16 males (mean
age 43 7.5 yr; range 26–58 yr). All controls were healthy with no
coexistent disease; this was determined from their medical records,
which included reports of a complete physical examination, routine
blood and urine tests, and chest radiographs. The study was done
according to the Declaration of Helsinki. All the patients and
controls gave informed consent.
Quality of life assessment
HRQOL was assessed using the SF-36 questionnaire. The SF-36
is a generic instrument with scores that are based on responses
to individual questions, which are summarized into eight scales,
each of which measures a health concept [11]. These scales
include function domains and aspects of well-being, as follows:
physical function (PF), limitations in physical activities because
of health problems; role–physical (RP), limitations in usual role
activities because of physical health problems; bodily pain (BP),
inﬂuence of pain on daily activities; vitality (VT), energy level
and fatigue; role–emotional (RE), limitations in usual role
activities because of emotional problems; mental health (MH),
psychological distress and well-being; social function (SF),
limitations in social activities because of physical or emotional
problems; general health (GH), subjective perception of health
status.
These eight scales, weighted according to normative data,
are scored from 0 to 100, higher scores reﬂecting better HRQOL
[12]. The SF-36 survey also includes a single-itemmeasure of health
transition, which is not used to score any of the eight multi-item
scales. The SF-36 has been validated for use in Italy [13] and
it can be completed within 10min by most people. Recently, the
originators of the SF-36 have developed algorithms to calcu-
late two psychometrically based summary measures: the physical
component summary (PCS) score and the mental component
summary (MCS) score [14, 15]. The PCS and MCS provide greater
precision, reduce the number of statistical comparisons needed,
and eliminate the ﬂoor and ceiling effects noted in several of
the subscales [16, 17].
Statistical analysis
Scores are variables measured on an ordinal scale and their
distributions showed a signiﬁcant difference from normality,
especially in the SLE group; consequently a non-parametric
statistic was used. The Mann–Whitney U test was used for
independent samples. Linear correlation between variables was
checked using Spearman’s . Dichotomous variables were ana-
lysed using the Pearson’s 2 test. Statistical signiﬁcance was set at
P<0.05. The median and range and the mean S.D. are presented.
All analysis were performed using the statistical software package
Statistica (Statsoft, Tulsa, OK, USA).
Results
The prominent clinical and serological features of our out-patients
are reported in Table 1. At the time of our evaluation the patients
had an average ECLAM score of 1.67 1.12 (range 0–6). Twenty-
ﬁve patients (18%) had damage in at least one of the organ systems
considered in the SLICC/ACR damage index. The mean damage
index score in our 126 patients was 0.33 0.84 (range 0–5). Taking
into account only the 25 patients with damage, the score was
1.68 1.14 (range 1–5).
In SLE patients, the PCS and the MCS scores were both lower
than in controls. PCS was 67.73 21.02 in SLE and 82.47 5.07 in
controls (P<0.00001), and MCS was 67.86 20.09 in SLE and
77.58 5.01 in controls (P<0.04).
In Table 2, the mean scores obtained in each of the eight SF-36
subscales in the patient and control groups are reported. In all
subscales the mean scores were lower in SLE patients than in
controls. The differences were statistically signiﬁcant for all
subscales except RP and SF. The major differences were observed
in GH and VT scores (both P<0.00001). In healthy subjects, the
frequencies of each score obtained in all subscales followed a
distribution with the mode located in the range of the highest
TABLE 1. Prominent SLE features overall and at the time of evaluation in
126 patients enrolled in the study
Cumulative
At the time of
evaluation
n (%) n (%)
Arthritis 94 (74.6) 9 (7.14)
Artralgias 110 (87.3) 33 (26.2)
Skin rash 67 (53.2) 9 (7.14)
Raynaud’s phenomenon 59 (46.8) 27 (21.4)
Serositis 33 (26.2) 7 (5.5)
Haematological involvement 103 (81.7) 62 (49.2)
Renal involvement 49 (38.9) 27 (21.4)
CNS involvement 13 (10.3) 4 (3.2)
Anti-dsDNA 96 (76.2) 64 (50.8)
Anti-RNP 53 (42.1) 37 (29.4)
Anti-Ro/SSA 54 (42.8) 37 (29.4)
Anti-La/SSB 15 (11.9) 9 (7.14)
Anti-aCL 39 (30.9) 48 (38)
LAC 27 (21.4) 20 (15.9)
For deﬁnitions of SLE speciﬁc features, we used those included in the
ACR criteria [7].
CNS, central nervous system; anti-dsDNA, anti-double-stranded DNA
antibody; anti-aCL, anticardiolipin antibody; LAC, lupus anticoagulant.
TABLE 2. Mean and standard deviation of the eight SF-36 subscales in
the patient and control groups
Mean S.D.
SF-36 subscale SLE (126 cases) Controls (96 cases) P<
PF 83.2 17.3 90.1 9.1 0.015
RP 69.8 37.9 81.7 8.5 n.s.
BP 68.7 26.3 78.8 11.0 0.011
GH 49.1 22.7 79.3 7.4 0.00001
VT 57.9 19.6 71.2 10.7 0.00001
SF 74.0 26.1 81.7 8.7 n.s.
RE 72.0 38.3 80.9 9.8 0.020
MH 67.6 21.0 76.5 8.4 0.022
Signiﬁcance was tested with the Mann–Whitney U test (n.s., not
signiﬁcant).
PF, physical function; RP, role–physical; BP, bodily pain; GH, general
health; VT, vitality; SF, social function; RE, role–emotional; MH, mental
health.
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scores, whereas in SLE the frequencies were spread along the whole
scale (Fig. 1A and B).
Looking at the effect of age on these measures, we observed
a signiﬁcant inverse linear correlation for all subscales and PCS
andMCS in SLE group, whereas no linear correlations were found
in the control group (Table 3 and Fig. 2).
In Table 4, the values of PCS and MCS distributed according
to age class are reported. In SLE, compared with controls, the
PCS score was lower in the age class 35–44 yr (P¼ 0.04), 45–54 yr
(P¼ 0.0001) and the MCS score was lower in the age class 45–54 yr
(P¼ 0.001), whereas no differences were noted in the age class
25–34 yr, i.e. the most common age class for disease onset.
While in the control group we observed very few correlations
among the different subscales (Table 5A), in SLE we noticed a
signiﬁcant correlation among the scores obtained in the different
subscales (Table 5B). In particular, in SLE, the VT subscale was
correlated with three of the four subscales of PCS: PF, RP and BP.
There was a signiﬁcant linear correlation (¼ 0.64, P<0.00001)
between the PCS and the MCS score in the patient group, which
was lacking in the control group (¼ 0.18, P¼ 0.07).
The PCS was higher than MCS in 81% of the controls and in
48.4% of the patients (2¼ 24.6, P¼ 0.00001).
Discussion
We considered a group of SLE patients regularly followed in our
division. Since they were all out-patients their mean disease activity
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FIG. 1. (A) Frequencies of scores on the GH (general health) scale in patients and controls. (B) Frequencies of scores on the VT
(vitality) scale in patients and in controls.
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was low, as expected. The mean damage index was also low,
probably due to their young mean age and their Caucasian race. In
this cohort of patients, HRQOL was lower than that observed in
healthy subjects. Our data concur with those reported by others
[6, 18–21] who considered a cohort of patients similar to our cohort
in term of disease activity and damage. However, other authors
[22, 23] observed an even lower HRQOL in groups of patients
with higher disease activity and damage index scores (Table 6).
The high standard deviation we observed in our SLE patients,
but not in our controls, suggests that SLE has a variable impact on
the patient’s life [24, 25]. This difference could be due to two types
of factors: the variability of the disease characteristics and course,
and the inﬂuence of the patient’s personality. The latter inﬂuences,
positively or negatively, adaptation to the illness.
Moreover, if we analyse the distribution of the scores of the
single subscales, we can see that low scores are frequently observed
in SLE patients, probably because some of them are forced to
drastically reduce or even discontinue activities usually considered
an essential part of daily life such as work, school or social
relationships. The most compromised scales were GH and VT. In
GH the patient expresses a global evaluation of his/her own health
and its decrease underlines a sensation of general reduction of
physical wellbeing. The worsening of VT has even more severe
implications: being an index of the energy level experienced by the
subject, its reduction can be due to physical causes as well as to the
sensation that even the psychological energies necessary to face
both everyday reality and planning of the future are missing.
SLE is traditionally considered a disease with great impact on
all aspects of health status. In patients, but not in controls, we
observed a progressive decrease in both PCS and MCS scores,
starting from age class 25–34 yr and continuing to decrease in the
45–54 and 55–64 classes. These progressive changes in HRQOL
could be due to several factors, such as SLE progression along the
years, continuously coping with a chronic illness, and practical
management items that may be required (frequent medical visits,
laboratory examinations, etc.). However, it is worth noting that
in the age group 18–24 yr HRQOL was lower than that observed
in the age groups 25–34 and 35–44 yr, apparently in contrast
with what we have stated previously. A possible explanation is
that the diagnosis of a chronic illness has a stronger effect in terms
of compromising HRQOL at an age at which physical, psycho-
logical and social stability has not yet been reached.
The difference we noted in the PF scale may be due to the
combined inﬂuence of age and the effect of the illness: both factors
can contribute in limiting the physical activities that a patient can
carry out freely.
It is worth noting that VT was inﬂuenced by the age class in SLE
patients but not in healthy people, probably because the latter do
not have to spend energy in balancing the physical limitations due
to illness.
In the SLE group, the subscale of VT signiﬁcantly correlated
with three of the four scales of the PCS. Therefore it seems
that this scale, in the presence of illness, works as a link between
physical and mental aspects, probably because VT has both
physical (fatigue, weakening) and psychological (demotivation,
depressed mood, tension) characteristics. It is interesting to
note that, in our sample, fatigue evaluated by the clinician
and deﬁned as a symptom which limits daily life activities, was
observed in only seven patients among 126 (5.5%), whereas VT
was, together with GH, the most compromised subscale according
to the patients’ perspective [16]. This observation conﬁrms the
strong impact that subjectivity has in modulating the effects of
an event on everyday life.
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FIG. 2. Trend of the mean of the two total scales for age classes and groups. PCS, physical component summary; MCS, mental
component summary.
TABLE 3. Linear correlation between age and SF-36 subscale scores in the
SLE and control groups
SLE patients (126 cases) Controls (96 cases)
SF-36 subscale  P<  P
PF 0.33 0.0002 0.07 n.s.
RP 0.24 0.009 0.14 n.s.
BP 0.29 0.001 0.08 n.s.
GH 0.22 0.013 0.07 n.s.
VT 0.35 0.00005 0.18 n.s.
SF 0.20 0.03 0.08 n.s.
RE 0.21 0.02 0.11 n.s.
MH 0.22 0.015 0.04 n.s.
PCS 0.32 0.0005 0.04 n.s.
MCS 0.27 0.002 0.01 n.s.
PF, physical function; RP, role–physical; BP, bodily pain; GH, general
health; VT, vitality; SF, social function; RE, role–emotional; MH, mental
health; PCS, physical component summary; MCS, mental component
summary; n.s., not signiﬁcant.
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Unlike what was observed in healthy subjects, in SLE patients
PCS and MCS and the single subscales were strongly correlated
with each other. Suffering from a chronic illness probably has a
central role in the patient’s life, since he/she could be forced to
revise some aspects of everyday life, including social relationships
as well as job adjustment [21, 26]. These changes are due to physical
reasons, but they can inﬂuence the psychosocial life of the patient.
In fact, if we consider the fact that PCS was higher than MCS
more frequently in the control group compared with the patients,
in agreement with other authors [21, 27], we can hypothesize that it
is PCS which inﬂuences MCS in SLE patients. In fact, the most
relevant factor in differentiating the two groups is indeed health.
While in healthy subjects the mental dimension is probably
inﬂuenced by various factors of everyday life, in an ill person
attention is focused on health problems, which in turn amplify the
everyday discomfort that everyone has to face.
There are some limitations of this study that should be
considered and addressed in future research studies. The cross-
sectional design prevented us from measuring any change in
HRQOL that may have occurred over time. A longitudinal study is
TABLE 5. Correlation coefﬁcients between the eight subscales
PCS MCS
SF-36 subscale PF RP BP GH VT SF RE MH
(A) Control group
PF 1.00 0.11 0.19 0.02 0.08 0.08 0.07 0.05
RP 1.00 0.01 0.09 0.22 0.34 0.08 0.10
BP 1.00 0.06 0.25 0.02 0.15 0.01
GH 1.00 0.12 0.13 0.26 0.04
VT 1.00 0.09 0.07 0.16
SF 1.00 0.05 0.09
RE 1.00 0.32
MH 1.00
(B) Patient group
PF 1.00 0.59 0.55 0.41 0.60 0.38 0.27 0.27
RP 1.00 0.67 0.41 0.62 0.48 0.49 0.36
BP 1.00 0.44 0.58 0.51 0.34 0.43
GH 1.00 0.48 0.49 0.34 0.47
VT 1.00 0.54 0.49 0.61
SF 1.00 0.47 0.49
RE 1.00 0.48
MH 1.00
Bold type indicates P<0.05.
PF, physical function; RP, role–physical; BP, bodily pain; GH, general health; VT, vitality; SF, social function; RE, role–emotional; MH, mental
health; PCS, physical component summary; MCS, mental component summary.
TABLE 6. Comparison of SF-36 scores, damage and activity indices in our patients and in other published series
Author (reference) Patients (n)
SF-36
SLICC/ACR: mean S.D. or
median (range)
Disease activity
MCS PCS
Score: mean S.D. or
median (range) Activity index
Thumboo [20] 90 69.2 19.4 65.1 19.9 0 (0–6) 2 (0–19) BILAG
Stoll [21] 60 64.4 19.1 n.r. 0.5* (0–5) 4.8 (1–11) BILAG
Da Costa [22] 59 46.1 11.5 37.6 11.1 1.5 1.9 (0–8) 6.6 3.5 SLAM-R
6.2 5.1 SLEDAI
Wang [23] 54 43.1 12.3 38.6 10.9 1.8 2.8 6.3 4.1 SLAM-2
Present study 126 67.9 20.1 67.7 21.0 0.33 0.84 (0–5) 1.7 1.1 ECLAM
*S.D. not reported; n.r., not reported.
PCS, physical component summary; MCS, mental component summary.
TABLE 4. Mean and S.D. of total scores (physical and psychological) in the two groups, divided into age classes
PCS MCS
Age class (yr) Patients (n) Controls (n) Patients Controls P Patients Controls P
18–24 9 0 64.4 18.4 67.6 18.0
25–34 49 19 76.0 16.4 81.9 5.7 n.s. 74.0 19.4 77.1 5.5 n.s.
35–44 27 24 69.0 20.4 82.4 4.3 0.04 70.9 18.8 77.7 5.6 n.s.
45–54 23 49 60.6 24.1 82.9 5.1 0.0001 63.1 19.7 77.7 4.7 0.001
55–64 16 4 55.1 23.0 80.5 6.5 n.s. 49.9 23.3 77.6 5.0 n.s.
65–74 2 0 44.7 11.3 76.1 3.0
PCS, physical component summary; MCS, mental component summary.
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needed to validate our ﬁndings and to explore the causal relation-
ship between physical involvement and mental factors.
In conclusion, HRQOL is signiﬁcantly reduced in SLE patients,
both in its physical and mental components, and this decrease is
characterized by a high correlation between the two dimensions.
It is likely that suffering from an organic illness reduces mental
well-being. However, once this negative connection is settled, the
inﬂuence might become mutual. This means that, along with the
progression of the illness, attention has to be focused on the way
physical symptoms inﬂuence the patient’s everyday life, in order
to prevent psychosocial difﬁculties from amplifying clinical com-
plaints. For this purpose it might be useful to look at the VT as
a reference index because it represents a connection between the
physical and mental dimensions. In addition, since age causes a
worsening of HRQOL greater than expected in patients, greater
attention should be paid to this process as patients gets older.
The authors have declared no conﬂicts of interest.
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Key messages
 In patients with SLE psychosocial difﬁ-
culties may amplify clinical complaints.
 Thus, it is important to evaluate not only
the severity of the physical symptoms
but also their inﬂuence on the patient’s
everyday life.
 VT may be used as a reference
index because it represents a connec-
tion between the physical and mental
dimensions.
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